EVAX — Evaxion Biotech A/S

Evaxion Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Evaxion reported a quarterly income of $4.6 million, primarily driven by a $7.5 million option exercise fee from MSD (Merck).
• Cash Position: The cash balance at the end of Q3 was $10.6 million, with a cash runway extended into the second half of 2027.
• Equity: Total equity increased to $16.6 million, bolstered by a debt-to-equity conversion with the European Investment Bank and warrant exercises totaling $2.7 million.
• Operating Expenses: Managed effectively, remaining stable compared to the previous year and quarter.

2. Strategic Updates and Business Highlights

• Leadership Transition: Dr. Helen Tayton-Martin will take over as CEO on November 24, 2025, bringing extensive biotech experience.
• Partnerships: The successful in-licensing of EVX-B3 by MSD is a significant milestone, validating Evaxion's AI-Immunology platform and R&D pipeline.
• Pipeline Developments: Introduction of EVX-04, a novel therapeutic cancer vaccine for acute myeloid leukemia (AML), and encouraging two-year clinical data for EVX-01 presented at ESMO Congress.
• AI-Immunology Platform: Enhanced with an automated vaccine design module, improving efficiency and reducing development timelines.

3. Forward Guidance and Outlook

• Evaxion is on track to meet its 2025 milestones, with ongoing partnership discussions and potential for further R&D updates.
• The company aims to out-license EVX-01 at its current development stage and is exploring applications of its technology in other cancer indications.

4. Bad News, Challenges, or Points of Concern

• Market Uncertainty: Ongoing partnership discussions are affected by market conditions, which may slow deal-making.
• EVX-B2 Evaluation: The evaluation period for EVX-B2 has been extended, indicating potential delays in decision-making from MSD regarding further funding.
• Competitive Landscape: The need to validate the AI-Immunology platform and demonstrate its effectiveness in various cancer indications amidst increasing competition in the biotech sector.

5. Notable Q&A Insights

• Partnership Discussions: Questions from analysts indicated a shift in focus from data quality to potential applications of technology in other cancer types, highlighting growing interest from partners.
• EVX-01 Data: The two-year clinical data for EVX-01 has been well-received, with discussions now focusing on how to leverage this data for future partnerships.
• EVX-04 Targeting: The new AML vaccine candidate is based on endogenous retroviral sequences, allowing for a shared vaccine approach across patients, which could enhance its marketability.
• MSD Relationship: MSD is currently evaluating data for EVX-B2, with expectations for feedback in the first half of next year, indicating ongoing engagement but also uncertainty regarding future funding.

Overall, Evaxion demonstrated strong financial performance and strategic progress in Q3 2025, while facing challenges related to market conditions and the pace of partnership developments.